Related Experiment Video
Updated: May 7, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Sunitinib in metastatic renal cell carcimoma: a single-center experience
V M Krishna1, V Noronha, K Prabhash
1Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Introduction:
Historically, metastatic renal cell carcinoma (RCC) has had poor prognosis; the outcomes have improved with the introduction of tyrosine-kinase inhibitors, such as sunitinib. There is no reported literature from India on the use of sunitinib in metastatic RCC. We present an analysis of sunitinib at our institute over 4 years.
Materials And Methods:
An unselected population of patients with metastatic or relapsed metastatic RCC receiving sunitinib was analyzed with respect to patient characteristics, response, toxicity, and outcomes.
Results:
Fifty-nine patients (51 males, 8 females) with a median age of 55 years were included in the study. Lungs and bones were the most common site of metastases. The patients received a median number of 4 cycles, with 23 patients requiring dose-modification and 12 discontinuing therapy due to toxicity. Overall, 38 patients (65%) had CR, PR, or standard deviation while 14 had progression or death at initial evaluation. The median progression-free survival (PFS) was 11.4 months and overall survival was 22.6 months. Hand-foot syndrome, fatigue, mucositis, skin rash, and vomiting were seen more often among our patients, whereas hypertension was not as common compared with previously published reports.
Conclusion:
Sunitinib is a viable option for the treatment of metastatic RCC and shows a comparable PFS in Indian patients. Although toxicity remains a concern, most of the adverse effects can be managed conservatively. Careful patient selection, tailoring the dose of therapy, adequate counseling, and careful follow-up is essential for optimum therapy.
Insights
Sunitinib offers a viable treatment option for metastatic renal cell carcinoma (RCC) in Indian patients, demonstrating comparable progression-free survival. Careful management of side effects is key for optimal outcomes.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic renal cell carcinoma (RCC) historically had a poor prognosis.
- Tyrosine-kinase inhibitors like sunitinib have improved outcomes.
- Limited data exists on sunitinib use for metastatic RCC in India.
Purpose of the Study:
- To analyze the efficacy and safety of sunitinib in Indian patients with metastatic RCC.
- To report on patient characteristics, response, toxicity, and survival outcomes.
Main Methods:
- Retrospective analysis of an unselected population of 59 metastatic RCC patients treated with sunitinib.
- Evaluation of patient demographics, metastatic sites, treatment cycles, dose modifications, and reasons for discontinuation.
- Assessment of treatment response, progression-free survival (PFS), and overall survival.
Main Results:
- The median age was 55 years, with lungs and bones being common metastatic sites.
- Median PFS was 11.4 months and overall survival was 22.6 months.
- Common toxicities included hand-foot syndrome, fatigue, mucositis, skin rash, and vomiting; hypertension was less frequent than reported previously.
Conclusions:
- Sunitinib is a viable treatment for metastatic RCC in Indian patients, with comparable PFS.
- Toxicity is a concern but manageable with conservative approaches.
- Optimal therapy requires careful patient selection, dose tailoring, counseling, and follow-up.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
07:50Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018
